Investor FAQs

Show all

Bioblast is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.

Given the interest in the scientific and medical community regarding alternative therapeutic uses of our lead drug candidate, trehalose 90mg/mL IV solution, Bioblast has decided to concentrate internal development efforts exclusively on trehalose.
Information can be accessed directly through the Company's web site (http://BioBlast-pharma.com). Annual 20-F reports, quarterly reports filed in a 6-K, and other filings with the SEC can be accessed directly through the Company web site or through the Securities and Exchange Commission at  http://www.sec.gov.
37 Dereh Menachem Begin St.
15th Floor, Tel-Aviv, Israel
Bioblast common stock trades under the symbol “ORPN”.
Shares of Bioblast trade on the NASDAQ Global Market.
Bioblast announced the pricing of its initial public offering of ordinary shares in July 2014 at an initial public offering price of $11.00 per share.
The total number of shares outstanding for Bioblast is 16,391,770 .
Bioblast’s fiscal year-end is December 31st.
Interested investors may purchase shares of Bioblast through any registered broker.
No. Bioblast does not offer a Direct Stock Purchase Plan at this time.
Bioblast does not currently pay a dividend to its stockholders.
VStock Transfer, LLC,
77 Spruce Street, Suite 201 Cedarhurst,
New York 11516
Facsimile: (646) 536-3179
Bioblast’s independent auditor is Kost Forer Gabbay & Kasierer (a Member of Ernst & Young Global).
For investor relations, please contact the following individuals:

LifeSci Advisors Contact
Matthew P. Duffy
Managing Director
212-915-0685
Matthew@LifeSciAdvisors.com

Bioblast Investor Relations Contact
ir@bioblastpharma.com